Simon D Roger

Summary

Affiliation: New South Wales
Country: Australia

Publications

  1. ncbi Biosimilars: opportunity or cause for concern?
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Australia
    J Pharm Pharm Sci 10:405-10. 2007
  2. ncbi Biosimilars: current status and future directions
    Simon D Roger
    Renal Unit, Gosford Hospital, Holden Street, Gosford, 2250, NSW, Australia
    Expert Opin Biol Ther 10:1011-8. 2010
  3. ncbi Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Gosford, Australia
    J Am Soc Nephrol 15:148-56. 2004
  4. ncbi Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study
    Jill S Lindberg
    New Orleans Nephrology Associates, 4228 Houma Boulevard, Metairie, LA 70006, USA
    J Am Soc Nephrol 16:800-7. 2005
  5. ncbi Biosimilars: how similar or dissimilar are they?
    Simon D Roger
    Renal Unit, Gosford Hospital, Gosford, New South Wales, Australia
    Nephrology (Carlton) 11:341-6. 2006
  6. ncbi What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia
    Nephrology (Carlton) 9:223-8. 2004
  7. ncbi Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial
    Lawrence P McMahon
    Department of Renal Medicine, Eastern Health, Melbourne, Victoria, Australia
    Nephrol Dial Transplant 25:920-6. 2010
  8. ncbi C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Gosford, Australia
    Nephrol Dial Transplant 26:3980-6. 2011
  9. ncbi A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease
    Simon D Roger
    Renal Research, Gosford, Australia
    Curr Med Res Opin 24:2181-7. 2008
  10. ncbi Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients
    Adrian D Hibberd
    Newcastle Transplant Unit, Division of Surgery, John Hunter Hospital, Newcastle, New South Wales, Australia
    Transplantation 81:711-7. 2006

Collaborators

Detail Information

Publications19

  1. ncbi Biosimilars: opportunity or cause for concern?
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Australia
    J Pharm Pharm Sci 10:405-10. 2007
    ..This review focuses on the issues surrounding biosimilars, including manufacturing, quality control, clinical efficacy and side effects, and how government and industry regulations are evolving to deal with these topics...
  2. ncbi Biosimilars: current status and future directions
    Simon D Roger
    Renal Unit, Gosford Hospital, Holden Street, Gosford, 2250, NSW, Australia
    Expert Opin Biol Ther 10:1011-8. 2010
    ..However, there have been concerns over the degree of similarity of these complex drugs in addition to the hope that their introduction may lower the cost of such expensive medicinal products...
  3. ncbi Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Gosford, Australia
    J Am Soc Nephrol 15:148-56. 2004
    ..The maintenance of [Hb] above 100 g/L for many patients in group B might have been attributable to the relative preservation of renal function...
  4. ncbi Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study
    Jill S Lindberg
    New Orleans Nephrology Associates, 4228 Houma Boulevard, Metairie, LA 70006, USA
    J Am Soc Nephrol 16:800-7. 2005
    ..Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis...
  5. ncbi Biosimilars: how similar or dissimilar are they?
    Simon D Roger
    Renal Unit, Gosford Hospital, Gosford, New South Wales, Australia
    Nephrology (Carlton) 11:341-6. 2006
    ....
  6. ncbi What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia
    Nephrology (Carlton) 9:223-8. 2004
    ..The recommended conversion dose for changing from epoetin alfa to darbepoetin alfa is 200 units to 1 microg. However, this may result in the over treatment of uraemic anaemia...
  7. ncbi Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial
    Lawrence P McMahon
    Department of Renal Medicine, Eastern Health, Melbourne, Victoria, Australia
    Nephrol Dial Transplant 25:920-6. 2010
    ..An optimal haemoglobin (Hb) response to erythropoietin requires elevated iron indices in dialysis patients; however, it is unknown if the same applies in chronic kidney disease (CKD)...
  8. ncbi C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis
    Simon D Roger
    Department of Renal Medicine, Gosford Hospital, Gosford, Australia
    Nephrol Dial Transplant 26:3980-6. 2011
    ..E.R.A.) Q4W with darbepoetin alfa once weekly (QW) or every 2 weeks (Q2W) for the correction of anaemia in non-dialysis CKD patients...
  9. ncbi A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease
    Simon D Roger
    Renal Research, Gosford, Australia
    Curr Med Res Opin 24:2181-7. 2008
    ..To compare injection site pain of subcutaneous (sc) epoetin beta and darbepoetin alfa in adult patients with chronic kidney disease...
  10. ncbi Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients
    Adrian D Hibberd
    Newcastle Transplant Unit, Division of Surgery, John Hunter Hospital, Newcastle, New South Wales, Australia
    Transplantation 81:711-7. 2006
    ..The aim of this study was to determine the bioequivalence of Cysporin, a generic cyclosporine A, compared with Neoral in stable renal transplant recipients...
  11. ncbi Understanding epoetin use: databases or clinical trials?
    Simon D Roger
    Nephrology (Carlton) 12:118-9. 2007
  12. ncbi Chronic kidney disease, anemia, and epoetin
    Simon D Roger
    N Engl J Med 356:958; author reply 958-9. 2007
  13. ncbi Epoetin trials: randomised controlled trials don't always mimic observational data
    Simon D Roger
    Nephrol Dial Transplant 22:684-6. 2007
  14. ncbi Effect of early correction of anemia on the progression of CKD
    Jerome Rossert
    Paris Descartes University, INSERM U652, AP HP, Georges Pompidou European Hospital, Paris, France
    Am J Kidney Dis 47:738-50. 2006
    ..This study is designed to assess the effect of early and complete correction of anemia by using recombinant human erythropoietin (epoetin) alfa on the progression of chronic kidney disease (CKD)...
  15. ncbi Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis
    Michelle J Irving
    Centre for Kidney Research, The Children s Hospital at Westmead, Sydney, NSW, Australia
    Med J Aust 185:310-4. 2006
    ..To evaluate the outcomes of and barriers to implementing standard guidelines (Caring for Australasians with renal impairment [CARI]), using iron management in patients having dialysis as an example...
  16. ncbi Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
    Tim Clayton
    Western Infirmary, Glasgow, UK
    Circulation 113:986-94. 2006
    ..In heart failure, the causes of anemia and the associations between anemia and outcomes are probably multiple and complex...
  17. ncbi Fistula dysfunction secondary to a subcutaneous myelomatous deposit
    David Boshell
    Department of Radiology, Westmead Hospital, Sydney, NSW 2031, Australia
    Nephrol Dial Transplant 20:2827-9. 2005
  18. ncbi Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease
    Lawrence P McMahon
    Department of Nephrology, Western and Royal Melbourne Hospitals, Melbourne, Victoria 3050, Australia
    J Am Soc Nephrol 15:1640-7. 2004
    ....
  19. ncbi Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?
    Jerome Rossert
    Nephrol Dial Transplant 17:359-62. 2002